Etanercept, an anti-TNF-α antibody that is a fusion protein between a human IgG1 Fc-tail and TNFR2, has been studied in murine models of AD with Aβ plaque formation and found to decrease TNF-α levels, reduce neuronal injury and improve cognitive measures [63,64]. The gene discussed is TNF; the disease is Alzheimer disease.